Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer

被引:5
|
作者
Huang, Yunxia [1 ]
Qiang, Yu [2 ]
Jian, Le [1 ]
Jin, Zhou [1 ]
Lang, Qian [1 ]
Sheng, Chen [2 ]
Shichong, Zhou [1 ]
Cai, Chang [1 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Ultrasonog,Dept Oncol, 270 Dongan Rd, Sanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Ultrasound; TP53; PIK3CA; Mutation; PATHWAY;
D O I
10.1016/j.acra.2022.02.021
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: To predict mutations in TP53 and PIK3CA genes in breast cancer using ultrasound (US) signatures and clinicopathology.Materials and Methods: In this study, we developed and trained a model in 386 breast cancer patients to predict TP53 and PIK3CA mutations. The clinicopathological and US characteristics (including two-dimensional and color Doppler US) were investigated. Statistically significant variables were used to build predictive models, then a combined model was developed using the multivariate logistic regression analysis.Results: Univariate and multivariate analyses revealed that calcifications on US was an independent predictor of TP53 mutation (p < 0.05), whereas diameter on US and US type were independent predictors of PIK3CA mutation in breast cancer (all p < 0.05). Meanwhile, Luminal B/Human epidermal growth factor receptor two-positive (HER2+), HER2+/estrogen receptor-negative (ER-), and triple-negative breast cancer (TNBC) subtypes were strong predictors of TP53 mutation (odds ratio [OR] = 3.13, 3.18, 3.44, respectively, all p < 0.05). HER2+/ER- and TNBC subtypes were negative predictors of PIK3CA mutation (OR = 0.223, 0.241, respectively, all p < 0.05). The areas under curves (AUCs) for PIK3CA mutation in the training set increased from 0.553-0.610 to 0.741 in the multivariate model that combined US features and molecular subtype, with a sensitivity and specificity of 80.6% and 58.7%, respectively. The application of the multivariate model in the validation set achieved acceptable discrimination (AUC = 0.715). For TP53 mutation, the AUC was 0.653.Conclusion: US is a non-invasive modality to recognize the presence of TP53 and PIK3CA mutation. The models combined with US features and molecular subtype have implications for the practical application of predicting gene mutation for individual decision-making regarding treatment planning. (c) 2022 The Association of University Radiologists. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页码:E261 / E270
页数:10
相关论文
共 50 条
  • [1] PIK3CA, MET and TP53 Gene Mutations in Penile Cancer
    Dhillon, Jasreman
    Spiess, Philippe E.
    Ryzhova, Elena
    Xiong, Yin
    Pow-Sang, Julio
    Magliocco, Anthony M.
    [J]. LABORATORY INVESTIGATION, 2016, 96 : 225A - 225A
  • [2] PIK3CA, MET and TP53 Gene Mutations in Penile Cancer
    Dhillon, Jasreman
    Spiess, Philippe E.
    Ryzhova, Elena
    Xiong, Yin
    Pow-Sang, Julio
    Magliocco, Anthony M.
    [J]. MODERN PATHOLOGY, 2016, 29 : 225A - 225A
  • [3] PIK3CA and TP53 mutations predict overall survival of stage Ⅱ/Ⅲ colorectal cancer patients
    A-Jian Li
    Hua-Guang Li
    Er-Jiang Tang
    Wei Wu
    Ying Chen
    Hui-Hong Jiang
    Mou-Bin Lin
    Lu Yin
    [J]. World Journal of Gastroenterology, 2018, (05) : 631 - 640
  • [4] Correlation analysis between PIK3CA, TP53, CDH1 genes mutations and breast cancer
    Zhu, Dongyue
    Gu, Yunjing
    Zhu, Ping
    [J]. 2018 17TH INTERNATIONAL SYMPOSIUM ON DISTRIBUTED COMPUTING AND APPLICATIONS FOR BUSINESS ENGINEERING AND SCIENCE (DCABES), 2018, : 308 - 313
  • [5] Implications of somatic TP53 and PIK3CA mutations in patients with metastatic breast cancer who underwent germline BRCA testing
    Yam, Clinton
    Barrera, Angelica Gutierrez
    Huang, Davis
    Lin, Xinyi
    Litton, Jennifer K.
    Arun, Banu
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [6] Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
    Li, Guoli
    Guo, Xinwu
    Chen, Ming
    Tang, Lili
    Jiang, Hui
    Day, Julia X.
    Xie, Yueliang
    Peng, Limin
    Xu, Xunxun
    Li, Jinliang
    Wang, Shouman
    Xiao, Zhi
    Dai, Lizhong
    Wang, Jun
    [J]. PLOS ONE, 2018, 13 (09):
  • [7] Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer
    Chang, Pi-Yueh
    Chen, Jinn-Shiun
    Chang, Shih-Cheng
    Wang, Mei-Chia
    Chang, Nai-Chung
    Wen, Ying-Hao
    Tsai, Wen-Sy
    Liu, Wei-Hsiu
    Liu, Hsiu-Ling
    Lu, Jang-Jih
    [J]. ONCOTARGET, 2017, 8 (42) : 72352 - 72362
  • [8] PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients
    Yao, Jun
    You, Qing
    Zhang, Xin
    Zhang, Yu
    Xu, Jiapeng
    Zhao, Xiaokai
    Li, Jieyi
    Wang, Xintao
    Gong, Ziying
    Zhang, Daoyun
    Wang, Weijun
    [J]. CLINICAL GENETICS, 2023, 103 (02) : 200 - 208
  • [9] The mutational profiles of PIK3CA and TP53 genes and some peculiar ultrastructural aspects in breast cancer
    Mihalcea, C. E.
    Morosanu, A. M.
    Murarasu, D.
    Puiu, L.
    Cinca, S.
    Voinea, S. C.
    Mirancea, N.
    [J]. FEBS JOURNAL, 2017, 284 : 147 - 147
  • [10] Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis
    Lin, Xiao-Yi
    Guo, Lijuan
    Lin, Xin
    Wang, Yulei
    Zhang, Guochun
    [J]. JOURNAL OF BREAST CANCER, 2023, 26 (04) : 363 - 377